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ABSTRACT
Background. Acute respiratory failure (ARF) is a life-threatening complication
in patients with community acquired pneumonia (CAP). The use of non-invasive
ventilation is controversial. With this prospective, observational study we aimed to
describe a protocol to assess whether a patient withmoderate-to-severe hypoxemic ARF
secondary to CAP benefits, in clinical and laboratoristic terms, from the application of
a positive end expiratory pressure (PEEP) + oxygen vs oxygen alone.
Methods. Patients who benefit fromPEEP application (PEEP-responders) were defined
as those with partial pressure of arterial oxygen to the fraction of inspired oxygen
(PaO2/FiO2) increase >20% and/or reduction of respiratory distress during PEEP
+ oxygen therapy compared to oxygen therapy alone. Clinical characteristics and
outcomes were compared between PEEP-responders and PEEP-non responders.
Results. Out of 41 patients, 27 (66%) benefit from PEEP application (PEEP-
responders), the best response was obtained with a PEEP of 10 cmH2O in 13 patients,
7.5 cmH2O in eight and 5 cmH2O in six. PEEP-responders were less likely to present
comorbidities compared to PEEP-non responders. No differences between groups were
found in regards to endotracheal intubation criteria fullfillment, intensive care unit
admission and in-hospital mortality, while PEEP-responders had a shorter length of
hospital stay.
Discussion. The application of a protocol to evaluate PEEP responsiveness might be
useful in patients with moderate-to-severe hypoxemic ARF due to CAP in order to
personalize and maximize the effectiveness of therapy, and prevent the inappropriate
PEEP use. PEEP responsiveness does not seem to be associated with better outcomes,
with the exception of a shorter length of hospital stay.
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INTRODUCTION
Acute respiratory failure (ARF) is a common life-threatening condition caused by the
inability of the respiratory system to maintain normal levels of oxygen and/or carbon
dioxide in the blood (Williams et al., 2012). Oxygen supplementation is the mainstay of
treatment for ARF, however, in more severe cases invasive mechanical ventilation (IMV)
may be required. IMV requires an intensive care unit (ICU) to be performed and is subdued
to high complications rates (Williams et al., 2012). Given these limitations, an increasing
number of patients with moderate to severe ARF receive a non-invasive ventilation (NIV)
trial before undergoing endotracheal intubation (ETI). The term NIV comprehends a
number of different ventilatory modes, including both continuous positive airway pressure
(CPAP) and bilevel positive airway pressure (BiPAP), and different patient-ventilator
interfaces, such as helmet and face or oronasal masks.
The efficacy of NIV in patients with ARFmainly depends on the severity and the cause of
the ARF itself (Nicolini et al., 2015; Ferrer, Cosentini & Nava, 2012; Ferrer & Torres, 2015).
The use of NIV should be limited to patients with less severe ARF (partial pressure of
arterial oxygen to the fraction of inspired oxygen [PaO2/FiO2] at presentation >150,
or PaO2/FiO2 after 1 h from NIV onset >175) with close monitoring and management
by experienced personnel in a high-dependency unit in order to detect early signs and
symptoms of NIV failure (Nicolini et al., 2015). NIV is also associated to a good response
in ARF patients with preexisting cardiac or respiratory diseases, such as pulmonary edema
and chronic obstructive pulmonary disease (COPD) exacerbations (Ferrer & Torres, 2015).
The use of NIV in patients with pneumonia is controversial, with the exception of
immunosuppressed patients, in whom NIV may decrease the need for IMV and improve
the poor outcome associated with ETI and ICU stay (Ferrer, Cosentini & Nava, 2012).
Recent evidence has shown that patients with moderate-to-severe hypoxemic ARF due
to pneumonia treated with CPAP delivered by helmet had a more rapid improvement
of arterial oxygenation and a lower risk of meeting ETI criteria when compared to the
standard oxygen therapy (Cosentini et al., 2010; Brambilla et al., 2014).
To date, the heterogeneity of the populations analyzed in the available studies has shown
that not all patients benefit from the application of a Positive End-Expiratory Pressure
(PEEP) (Ferrer & Torres, 2015; Luo et al., 2016).
Patients may not respond to CPAP application for several reasons, including intolerance
to the interface or pressure applied and development of hemodynamic instability (Ferrer &
Torres, 2015; Luo et al., 2016). The application of a protocol to readily distinguish patients
that benefit from PEEP application (PEEP-responders) from those that do not (PEEP-non
responders) could help to prevent ETI delay and inappropriate NIV use, to individualize
ventilatory and oxygenation support optimizing PEEP use.
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Primary aim of the present study is to describe a protocol that assesses whether a patient
with moderate-to-severe hypoxemic ARF due to CAP benefits, in clinical and laboratoristic
terms, from the application of a PEEP + oxygen therapy through helmet-CPAP vs oxygen
therapy alone. Secondary aim is to evaluate the prevalence, clinical characteristics and
outcomes of PEEP-responder in comparison to PEEP-non-responder patients.
MATHERIALS & METHODS
Study design
This was a single-center prospective cohort study of patients admitted with a diagnosis
of hypoxiemic ARF due to CAP who underwent a CPAP trial in the respiratory high
dependency unit (HDU), between January 2013 and August 2016. The institutional review
board of the hospital approved the study (#57/January 2013) and patients signed an
informed consent form.
Study population
Patients were included in the study if they presented all the following characteristics:
- age ≥ 18 years;
- diagnosis of CAP (healthcare associated pneumoniawas included in theCAPdefinition)
- acute hypoxiemic respiratory failure (PaCO2 ≤ 45 mmHg) with a PaO2/FiO2 ≤
200 during supplementation of oxygen with Venturi mask FiO2 35%, 50% or non-
rebreathing mask at a flow rate of 15 L/min for at least 20 consecutive minutes with a
target SpO2 ≥90%.
Patients with at least one among the following were excluded from the study:
• diagnosis of hospital-acquired pneumonia;
• concomitant diagnosis of undrained pneumothorax or pulmonary embolism;
• chronic CPAP use to correct obstructive sleep apnea syndrome (OSAS) if the same
mode and setting were maintained during hospitalization for pneumonia;
• unstable hemodynamic conditions;
• severe central neurological disturbance (e.g., comatose state);
• inability to protect respiratory airways;
• inability to fit the interface (e.g., facial trauma or burns);
• presence of open wound (skull, chest, abdomen);
• severe gastrointestinal bleeding;
• uncooperative patient;
• active pregnancy;
• respiratory arrest and ETI need;
• Concomitant diagnoses, such as COPD exacerbations and pulmonary edema, that
could have been the primary cause of ARF instead of pneumonia according to the
medical team in charge of the patient.
Data collection
Demographics, comorbidities, laboratory, microbiological and radiological tests performed
upon diagnosis of pneumonia, severity of the disease and antibiotic therapy used upon
Paolini et al. (2018), PeerJ, DOI 10.7717/peerj.4211 3/13
CPAP-trial were collected for all the enrolled patients. Patients were followed up till hospital
discharge. Length of CPAP application (in PEEP-responder patients) and adverse events
as well as intolerance related to CPAP application were also registered.
Modalities of CPAP application
CPAP was delivered in all patients enrolled in the study through a high-flow generator
(90–140 L/min; VitalSigns, Inc., San Antonio, TX, USA; StarMed, Mirandola, Italy) using
a helmet interface (StarMed, Mirandola, Italy) with a PEEP water valve (Harol, Milan,
Italy). To maintain stable FiO2 values at different PEEP levels, oxygen flow was modified in
accordance with the tables provided by the manufacturer. FiO2 was initially titrated with
a Venturi mask or non-rebreathing mask at a flow rate of 15 L/min to maintain a pulse
oximetry ≥90% for at least 20 min. CPAP was then applied with the same FiO2 setting
used with oxygen supplementation alone.
Study outcomes
The following primary end-points were evaluated:
- ETI criteria fullfillment: presence of at least one of the following major criteria or at least
two of the following minor criteria.
Major criteria:
- cardiac arrest;
- hemodynamic instability (SBP <90 mmHg, despite adequate fluid resuscitation);
- inability to protect the airways.
Minor criteria:
- PaCO2 increase ≥ 45 mmHg;
- significant worsening or onset of respiratory distress;
- neurological impairment (agitation requiring patient’s sedation);
- PaO2/FiO2 decrease >20% compared to baseline.
- Admission to ICU.
- In-hospital mortality: defined as death by any cause occurred during hospitalization.
The following were considered as secondary outcomes:
- Length of hospital stay (LOS): calculated as the number of days from the date of
admission to the date of discharge;
- Switch from CPAP to BiPAP ventilation: adding of a ‘‘Pression Support’’ (PS) in case of
onset or persistence of respiratory distress and/or PaCO2 increase ≥45 mmHg.
Trial planning and evaluation of response to FiO2 and PEEP
application
If a patient had a diagnosis of pneumonia, fullfilled all inclusion and exclusion criteria and
signed informed consent, he/she was eligible to participate in the study and to perform the
CPAP trial.
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Figure 1 Description of the CPAP-trial used to differentiate PEEP responder patients from PEEP-non
responder. PEEP, Positive End-Expiratory Pressure; CPAP, continuous positive airway pressure; FiO2,
fraction of inspired oxygen; RR, respiratory rate.
Full-size DOI: 10.7717/peerj.4211/fig-1
The steps of the CPAP trial are summarized in Fig. 1. During the clinical evaluation
performed in each step we measured vital signs, including blood pressure (BP), heart
rate (HR), and respiratory rate (RR), and evaluated the presence of respiratory distress,
defined as accessory muscles use and/or chest-abdominal dyssynchrony and paradoxical
respiration. Helmet-CPAP tolerance and level of consciousness (through patients’ response
to simple verbal commands if alert, or through eye opening, verbal and motor response if
not alert) were also assessed.
The definitions of PEEP-responder, FiO2-responder and PEEP-non and FiO2-non
responder are presented in Fig. 2. FiO2-responsiveness was evaluated comparing clinical
and arterial blood gas parameters during oxygen supplementation with Venturi mask
and helmet-CPAP PEEP 0 cmH2O, maintaining the same FiO2. A FiO2-responder is
defined as a subject with clinical and/or arterial blood gases improvement with helmet-
CPAP PEEP 0 cmH2O compared to Venturi mask, maintaining the same FiO2. PEEP-
responsiveness was evaluated comparing clinical and arterial blood gas parameters during
oxygen supplementation with helmet-CPAP PEEP 0 cmH2O and other PEEP levels (5, 7.5
and 10, respectively), maintaining the same FiO2. A PEEP-responder is defined as a subject
with clinical and/or arterial blood gases improvement with helmet-CPAP PEEP 5, 7.5 or
10 cmH2O compared to helmet-CPAP PEEP 0 cmH2O, maintaining the same FiO2.
Paolini et al. (2018), PeerJ, DOI 10.7717/peerj.4211 5/13
Figure 2 Definitions of PEEP-responder, FiO2 responder, PEEP-non and FiO2-non responder. PEEP,
Positive End-Expiratory Pressure; FiO2, fraction of inspired oxygen; RR, respiratory rate; CPAP, continu-
ous positive airway pressure. Significant changes in clinical or arterial blood gas parameters are intended
as an improvement or worsening of 20% compared to baseline.
Full-size DOI: 10.7717/peerj.4211/fig-2
Statistical analysis
Data were analyzed using SPSS 21.0 for MAC OS (SPSS Inc., Chicago, IL, USA). Baseline
characteristics of the study population, biomarkers levels, radiological features on
admission, and outcomes were considered for statistical analysis. Continuous variables are
expressed as median (interquartile range -IQR-25th–75th percentile) and compared using
Wilcoxon–Mann–WhitneyU two-sample test. Categorical data are expressed as frequencies
and percentages and compared using the chi-square or Fisher exact test, where appropriate.
All tests were 2-tailed and a p-value <0.05 was considered statistically significant.
RESULTS
CPAP-trial results
A total of 41 patients (median age 74 years, 71% males) were enrolled in the study.
Study population was divided according to the response to the CPAP-trial in two main
groups: PEEP-responders (27 patients, 66%) and PEEP-non responders (14 patients, 34%).
In the latter group, the reasons for PEEP-non responsiveness were as follows: 11 patients
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Table 1 Vital signs and arterial blood gas parameters during CPAP-trial.
Oxygen only PEEP 0 cmH2O PEEP 5 cmH2O PEEP 7.5 cmH2O PEEP 10 cmH2O
PaO2/FiO2, median [IQR]
Entire population 149 [131–178] 202 [147–268] 223 [172–315] 230 [168–296] 272 [167–354]
PEEP-responders 151 [136–173] 202 [126–257] 234 [189–328] 255 [195–302] 280 [209–361]
PEEP-non responders 145 [128–196] 227 [166–282] 210 [152–291] 208 [134–320] 175 [129–294]
RR, median [IQR]
Entire population 26 [20–31] 24 [20–30] 24 [20–29] 24 [21–29] 26 [21–29]
PEEP-responders 30 [20–33] 26 [24–30] 24 [22–30] 24 [22–28] 26 [23–29]
PEEP-non responders 20 [20–30] 23 [16–31] 23 [20–29] 25 [20–31] 25 [20–30]
PaCO2 (mmHg), median [IQR]
Entire population 37 [33–39] 38 [33–40] 37 [33–41] 37 [32–39] 38 [34–40]
PEEP-responders 37 [33–39] 36 [29–39] 36 [33–39] 36 [32–38] 37 [32–40]
PEEP-non responders 38 [36–40] 40 [37–41] 40 [36–43] 39 [33–43] 40 [37–43]
HR, median [IQR]
Entire population 86 [80–100] 81 [79–94] 80 [73–92] 87 [74–95] 86 [74–97]
PEEP-responders 80 [78–97] 80 [78–92] 80 [70–92] 81 [70–94] 82 [70–90]
PEEP-non responders 90 [80–106] 86 [79–97] 82 [75–98] 91 [76–98] 95 [78–103]
MAP, median [IQR]
Entire population 87 [80–93] 90 [81–100] 93 [83–99] 92 [86–106] 94 [88–104]
PEEP-responders 87 [81–94] 90 [81–100] 92 [83–97] 90 [83–100] 94 [85–104]
PEEP-non responders 84 [80–93] 86 [81–100] 93 [86–105] 103 [89–113] 98 [90–109]
Lactate (mMol/L), median [IQR]
Entire population 1.7 [1.1–1.9] 1.4 [1–1.9] 1.3 [1–2] 1.2 [1–2] 1.2 [0.9–1.6]
PEEP-responders 1.7 [1.1–2.1] 1.5 [1–1.9] 1.5 [0.9–2] 1 [1–2] 1.2 [1–1.5]
PEEP-non responders 1.3 [0.9–3.2] 1.3 [0.7–1.9] 1.2 [0.8–1.8] 1.3 [1–1.3] 1.2 [0.7–2.1]
Notes.
PEEP, Positive End Expiratory Pressure; PaO2/FiO2, partial pressure of arterial oxygen to the fraction of inspired oxygen; RR, respiratory rate; MAP, mean arterial pressure;
HR, heart rate.
showed unchanged or worsened clinical and arterial blood gas parameters (in terms of
oxygenation) during CPAP application, two patients (both with a history of COPD)
developed hypercapnia after CPAP application, and one patient experienced intolerance
to the interface.
PEEP-non responders were further subgrouped in FiO2-responders (11 patients—
27% of the entire study population) and PEEP-non and FiO2-non responders (three
patients—7% of the entire study population).
During the CPAP trial vital signs and arterial blood gas parameters were evaluated with
oxygen mask and with Helmet-CPAP at different PEEP levels (0, 5, 7.5 and 10 cmH2O),
Table 1.
Among the 27 PEEP-responder patients, the best response was obtained with a PEEP
level of 10 cmH2O in 13 patients, 7.5 cmH2O in eight patients, and 5 cmH2O in six
patients.
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Characteristics of study population
Demographics, comorbidities, laboratory tests and radiological features of the study
population are summarized in Table 2. No statistically significant differences were found
between groups in regards to demographics, laboratories and radiological features of
pneumonia upon execution of CPAP-trial. In regards to comorbidities, chronic liver
disease and chronic renal failure were more common in PEEP-non responder patients
compared to PEEP-responders.
Severity of the disease upon execution of CPAP-trial is summarized in Table 3. No
differences were found between groups both in regards to severity score (Sequential Organ
Failure Assessment (SOFA) score) and neurological and hemodynamic parameters.
Etiological diagnosis of CAP was reached in 16 patients (34%) and the following
microorganisms were the most commonly isolated: S. pneumoniae (six patients),
L. pneumophila (five patients), methicillin-resistant S. aureus (one patient), P . aeruginosa
(one patient),M. catarrhalis (one patient), P. Jiroveci (one patient), influenza B virus (one
patient), with no statistical significant difference between the two groups.
Antibiotic therapy was chosen in accordance with international guidelines and did not
differ between groups (Woodhead et al., 2011).
Helmet-CPAP tolerance and adverse events
Thirty-eight patients (93%) completed the CPAP trial. The reasons for CPAP-trial
interruption were PaCO2 increase≥45 mmHg in two cases and intolerance to the interface
in one case. In PEEP-non responder patients CPAP was immediately discontinued. In
the PEEP-responder group the median [IQR] length of CPAP treatment was 5 [3–7]
days. In this group of patients, helmet-CPAP was applied three cycles per day (morning,
afternoon and night) and each cycle consisted of at least a 3-hour application. If clinical
parameters and gas exchange allowed it, helmet-CPAP was interrupted for oral feeding
and personal hygiene. Helmet-CPAP usefulness was assessed on a daily basis through
clinical and hemogasanalytic evaluation; once respiratory failure and distress were solved
it was discontinued. None of the PEEP-responder patients developed discomfort, due to
intolerance to the interface and/or pressure applied, or pressure ulcers.
Cardiovascular complications developed in three cases (7%) during hospital stay, but
not during the CPAP-trial: two cases of new onset supraventricular tachyarrhythmia (one
PEEP-responder and one PEEP-non responder patient, respectively, p-value 1), and one
case of acute coronary syndrome in a PEEP-responder patient.
Study outcomes
Among the primary study outcomes, ETI criteria were fullfilled by one patient in the
PEEP-non responder group (simultaneous achievement of two minor criteria: onset of
respiratory distress and PaO2/FiO2 decrease >20% compared to baseline), regardless of
the presence of a do-not-intubate-do-not-resuscitate (DNI-DNR) order. One patient
(PEEP-responder) required ICU admission (one day after performing the CPAP-trial).
Three patients (7%) died during hospitalization with no statistically significant differences
between groups (one vs two patients in the PEEP-responder and PEEP-non responder
group, respectively, p-value 0.54).
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Table 2 Demographic and clinical characteristics of the study population.
Entire population (N = 41) PEEP-responders (N = 27) PEEP-non responders (N = 14) p-value
Demographics, n. (%)
Age (years), median [IQR] 74 [59–80] 68 [45–79] 78 [68–82] 0.055
Males 29 (71) 18 (67) 11 (79) 0.49
BMI (kg/m2), median [IQR] 25 [22.8–27.9] 25 [22.9–28.3] 25 [20.8–26.5] 0.61
Current or prior smokers 27 (66) 16 (59) 11 (79) 0.31
Comorbidities, n. (%)
Coronary artery disease 6 (15) 4 (15) 2 (14) 1
Valvular heart disease 2 (5) 2 (7) 0 0.54
Hypertension 18 (44) 14 (52) 4 (29) 0.2
Chronic arrhythmia 10 (24) 7 (26) 3 (21) 1
COPD 12 (29) 5 (19) 7 (50) 0.068
Pulmonary emphysema 6 (15) 2 (7) 4 (29) 0.16
Long-term oxygen therapy 4 (10) 2 (7) 2 (14) 0.6
Chronic renal failure 3 (7) 0 3 (21) 0.03
Chronic liver disease 6 (15) 1 (4) 5 (36) 0.01
Active solid cancer 2 (5) 0 2 (14) 0.11
Hematologic malignancy 7 (17) 4 (15) 3 (21) 0.66
Cerebrovascular disease 2 (5) 1 (4) 1 (7) 1
Dementia 1 (2) 1 (4) 0 1
Diabetes mellitus 7 (17) 6 (22) 1 (7) 0.39
Autoimmune disease 3 (7) 2 (7) 1 (7) 1
Immunosuppression 4 (10) 4 (15) 0 0.28
Laboratories, median [IQR]
WBC (×103/mL) 12.1 [7.8–16.5] 10.5 [7.8–14.2] 14.1 [7.8–21] 0.24
Hemoglobin (g/dL) 12.3 [11–13.3] 12.3 [11–13.6] 12.4 [10.5–13.2] 0.86
Platelets (×103/mL) 197 [137–265] 193 [132–263] 208 [142–293] 0.73
C-reactive protein (mg/dL) 19 [9.3–28.5] 15.7 [6.3–25] 25.3 [17–31.3] 0.07
Radiological features, n. (%)
Left upper lobe involvement 9 (22) 6 (22) 3 (21) 1
Left lower lobe involvement 17 (42) 12 (44) 5 (36) 0.74
Right upper lobe involvement 15 (37) 10 (37) 5 (36) 1
Middle lobe involvement 6 (15) 3 (11) 3 (21) 0.39
Right lower lobe involvement 21 (51) 12 (44) 9 (64) 0.33
Interstitial pneumonia 3 (7) 3 (11) 0 0.54
Unilobar involvement 18 (44) 14 (52) 4 (29) 0.2
Multilobar involvement 23 (56) 13 (48) 10 (71) 0.2
Notes.
PEEP, Positive End Expiratory Pressure; IQR, interquartile range 25th–75th percentile; BMI, body mass index; COPD, chronic obstructive pulmonary disease; WBC, white
blood cells.
Significant p-values (p< 0.05) are in bold.
Paolini et al. (2018), PeerJ, DOI 10.7717/peerj.4211 9/13
Table 3 Severity of the disease upon CPAP-trial execution.
Entire population
(N = 41)
PEEP-responders
(N = 27)
PEEP-non
responders
(N = 14)
p-value
Severity of the disease, n. (%)
SOFA score, median [IQR] 4 [3–4] 4 [3–4] 4 [3–4] 0.93
Alteration of mental status 2 (5) 1 (4) 1 (7) 1
Vasopressors use 3 (7) 3 (11) 1 (7) 0.54
Diuresis < 0.5 ml/kg/h 4 (10) 1 (4) 3 (21) 0.09
Hypotension requiring fluid 7 (17) 4 (15) 3 (21) 0.66
resuscitation
Among the secondary end-points, the median LOS showed a statistically significant
difference between study groups (13 days [IQR 9-18] in the PEEP-responder vs 18 days
[IQR 14-24] in the PEEP-non responder group, p-value 0.048). One PEEP-non responder
patient, who developed hypercapnia during the CPAP-trial, was switched from CPAP to
BiPAP ventilation.
DISCUSSION
In the present study we described a protocol to perform a rapid and repeatable CPAP trial
that allowed to select patients with hypoxemic ARF due to CAP who benefit from PEEP
application (PEEP-responders) and to determine the optimal PEEP level. No differences
were found between PEEP-responder and PEEP-non responder patients in regards to the
main clinical, laboratoristic and radiological features, with the exception of a higher burden
of comorbidities in PEEP-non responders. Failure to respond to PEEP application was
not associated with worse outcomes, with the exception of a significantly longer length of
hospital stay in PEEP-non responder patients.
In our cohort, 34% of patients with hypoxemic ARF due to CAP did not benefit from
PEEP application, thus, our protocol allowed a personalized approach and a limitation to
the inappropriate use of PEEP. Furthermore, among PEEP-non responders, our protocol
allowed the identification of patients that benefit from the application of high flow oxygen
(FiO2-responders), who might be the best candidates for high-flow nasal cannula trials.
There are also limited data on what is the optimal PEEP level to apply in patients
with ARF due to pneumonia (Cosentini et al., 2010; Brambilla et al., 2014). In the studies
conducted so far, a PEEP level of 10 cmH2O has been applied to all patients randomized
in the NIV arm (Cosentini et al., 2010; Brambilla et al., 2014). In our cohort, more than
half of the PEEP-responder patients showed a better clinical and hemogasanalytic response
with a PEEP value lower than 10 cmH2O. This result suggests that there is not a standard
PEEP applicable to all patients, but each subject requires an individualized value; however,
the factors that determine the response to a higher or lower PEEP level in patients with
pneumonia still need to be identified.
TheCPAP trial we proposed also allowed, for the first time, to compare the characteristics
of PEEP-responder vsPEEP-non responder patients.Wedid not find any difference between
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the two groups, with the exception of a lower burden of comorbidities in PEEP- responder
patients. In particular, no differences were found in regards to radiological features and
severity of the disease.
In our study CPAP was applied through helmet instead of face or oral-nasal mask. This
interface was well tolerated and showed few side effects (only one patient discontinued the
trial due to helmet intolerance). Our results are supported by other similar observations
by Brambilla et al. and Patel and colleagues, who confirmed the good tolerance to helmet in
patients with ARF due to pneumonia and ARDS (Acute Respiratory Distress Syndrome),
respectively (Brambilla et al., 2014; Patel et al., 2016).
In our cohort, we did not find statistically significant differences between PEEP-
responders and PEEP-non responders in regard to the primary outcomes, although
patients in the latter group were older, more likely to receive a DNR-DNI order and with
more comorbidities. Therefore, the failure to respond to PEEP application alone does not
seem to be a poor prognostic factor in patients with hypoxemic ARF due to CAP.
Among the secondary outcomes, we observed a longer duration of hospital stay in
PEEP-non responders. A possible explanation for this finding may lay, as already noted, in
the older age and the greater burden of comorbidities of these patients.
Finally, in our cohort we found that three patients, with no statistically significant
difference between PEEP- responders and PEEP-non responders, developed cardiovascular
complications during hospital stay, but not during CPAP trial. The increased incidence of
cardiovascular events in patients with pneumonia, up to a quarter of those admitted to
the hospital, has been extensively described in a series of papers by Corrales-Medina et al.
(2012).
To the best of our knowledge, this is the first study to describe a protocol to perform
a rapid and repeatable CPAP trial that allows to identify PEEP-responder patients and
the optimal PEEP level, however, a few limitations have to be highlighted. First of all,
although our study was conducted prospectively, the small number of patients recruited
in a single center and the use of helmet-CPAP as interface instead of face masks limit
the generalizability of the data and the possibility to perform further analyses on FiO2-
responder patients and different PEEP levels. Secondly, having carried out the trial only in
patients hospitalized in a respiratory HDU, a selection bias must be considered: patients
with low performance status, advanced age and multiple comorbidities were often not
considered eligible for admission in the respiratory HDU and, thus, excluded from the
study. Conversely, patients candidates to invasive maneuvers that showed a rapid clinical
deterioration at presentation may have been directly admitted to ICU for the incipient risk
of ETI. Thirdly, our cohort of patients was not homogeneous with regards to the temporal
phase of pneumonia: the CPAP trial was performed both in patients at early stages and in
post-acute stages of the disease (e.g., during weaning from IMV). Finally, we did not include
in the study a control group, because the application of the CPAP trial is standard-of-care
for all patients with moderate to severe hypoxemic ARF due to pneumonia admitted to
our respiratory HDU.
Future studies should aim to the external validation of the CPAP trial and to identify
the predictors of response to PEEP application.
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CONCLUSIONS
In conclusion, the application of theCPAP trial we proposedmight be useful in patientswith
moderate-to-severe hypoxemic ARF due to CAP in order to personalize and maximize the
effectiveness of therapy, and prevent the inappropriate use of PEEP. PEEP responsiveness
was not associated with better outcomes, with the exception of a shorter LOS.
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